Loading data for AUPH — first visit, this takes a few seconds.
Aurinia Pharmaceuticals I... (AUPH)
: AUPH
· Precio en tiempo real · USD
n/a
n/a (n/a)
Al cierre: Invalid Date
Aurinia Pharmaceuticals Inc. (AUPH) Stock Price, Analysis & Data
No hay datos disponibles
| Precio de compra | n/a |
| Capitalización de mercado | n/a |
| Ingresos (TTM) | 311.51M |
| Beneficio neto (TTM) | 314.11M |
| Beta | 1.40 |
| EPS (TTM) | n/a |
| Ratio PER (TTM) | n/a |
| Adelante PE | 14.34 |
| P/B (TTM) | 3.31 |
| P/S (TTM) | 6.53 |
| Earnings Date | n/a |
| Precio de venta | n/a |
| Volumen | NaN |
| Volumen medio (20D) | n/a |
| Abierto | n/a |
| Anterior Cerrar | n/a |
| Rango del día | n/a - n/a |
| Rango de 52 semanas | n/a - n/a |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de AUPH
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential tre...
Industria Biotechnology
Sector Healthcare
IPO Fecha Sep 3, 2014
Empleados 128
Bolsa de Valores NasdaqGM
Símbolo bursátil AUPH
Sitio web https://www.auriniapharma.com
Desempeño financiero
En 2025, los ingresos de Aurinia Pharmaceuticals fueron 283.06M, un aumento de 20.38% en comparación con 235.13M del año anterior. Las ganancias fueron 287.2M, un aumento de 4,893.08%.
Estados financieros